FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment Large, pivotal global study confirms ...
Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, prevents infants with the most severe form from gaining motor development - ...
TipRanks on MSN
Scholar Rock’s Phase 2 Study on Apitegromab: A Potential Game-Changer for SMA Treatment
Scholar Rock Holding (($SRRK)) announced an update on their ongoing clinical study. Scholar Rock Holding (SRRK) is currently conducting a Phase 2, ...
The study is designed as a cohort observational model with a prospective time perspective. Participants are followed throughout their pregnancy and up to 12 weeks postpartum, while their babies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback